Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported results of its Annual Meeting of stockholders held on June 4, 2026. Stockholders elected three Class II directors — Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. — to serve until the 2029 annual meeting, with each to continue until a successor is elected and qualified.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 99,637,228 votes for, 1,123 against, and 578,031 abstaining. In addition, stockholders approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 87,055,111 votes for, 3,491,326 against, and 577,257 abstaining.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for KPMG LLP: 99,637,228 votes
Votes for executive compensation: 87,055,111 votes
Votes for Laura Brege: 87,300,827 votes
+2 more
5 metrics
Votes for KPMG LLP
99,637,228 votes
Ratification of auditor for fiscal year ending December 31, 2026
Votes for executive compensation
87,055,111 votes
Advisory vote on named executive officers’ compensation
Votes for Laura Brege
87,300,827 votes
Election as Class II director until 2029 annual meeting
Votes for Badreddin Edris, Ph.D.
64,082,681 votes
Election as Class II director until 2029 annual meeting
Votes for Jonathan Root, M.D.
59,213,781 votes
Election as Class II director until 2029 annual meeting
Key Terms
Annual Meeting of stockholders, independent registered public accounting firm, advisory and non-binding basis, named executive officers, +1 more
5 terms
Annual Meeting of stockholders financial
"Edgewise Therapeutics, Inc. (the “Company”) held its Annual Meeting of stockholders"
independent registered public accounting firm financial
"the appointment of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory and non-binding basis financial
"The stockholders approved, on an advisory and non-binding basis, the compensation"
named executive officers financial
"the compensation of the Company’s named executive officers"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
Class II Directors financial
"Proposal 1: Election of three Class II Directors"
FAQ
What did Edgewise Therapeutics (EWTX) stockholders approve at the 2026 Annual Meeting?
Edgewise Therapeutics stockholders elected three Class II directors, ratified KPMG LLP as auditor for 2026, and approved, on an advisory and non-binding basis, the compensation of named executive officers. These actions confirm the company’s proposed board, auditor, and executive pay program.
Who was elected to the Edgewise Therapeutics (EWTX) board in 2026?
Stockholders elected Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D., as Class II directors to serve until the 2029 annual meeting. Each director will continue in office until a successor is duly elected and qualified, subject to earlier resignation or removal under company governance.
Which auditor did Edgewise Therapeutics (EWTX) stockholders ratify for 2026?
Stockholders ratified KPMG LLP as Edgewise Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote totaled 99,637,228 shares for, 1,123 against, and 578,031 abstaining, indicating strong stockholder support for continuing with the same audit firm.
How did Edgewise Therapeutics (EWTX) stockholders vote on executive compensation in 2026?
Stockholders approved, on an advisory and non-binding basis, the compensation of Edgewise Therapeutics’ named executive officers. The vote was 87,055,111 shares for, 3,491,326 against, and 577,257 abstaining, showing broad but not unanimous support for the company’s executive pay practices at this meeting.
When will the newly elected Edgewise Therapeutics (EWTX) directors’ terms expire?
The three elected Class II directors will serve until the 2029 annual meeting of stockholders. Their service continues until their successors are duly elected and qualified, or until earlier resignation or removal, following the company’s standard board term and transition framework.